AusBioInvest 2023 keynote speaker announced


A US venture capitalist with a track record of successful investing in Australian biotech will headline Australia’s premier life sciences investment conference, AusBioInvest 2023, in October.

Kanishka Pothula, Partner of Nextech Ventures (US), formerly with BVF Partners, a premier biotechnology-focused hedge fund where he had several billion under management, has been announced as a keynote speaker.

The US-based Australian ex-pat will deliver an engaging and interactive fireside discussion on ‘What biotech investors consider when evaluating a deal: a how-to for non-specialist investors’ at AusBioInvest in Melbourne on October 30, discussing health investment, and why it’s important to know what drives US investors when Australian companies are seeking seed and expansion capital offshore.

During this interactive fireside, Kanishka will provide insights on how US investors operate, factors US investors consider in dealmaking, and how this compares to Australian investment and dealmaking models, before passing to the audience for Q&A.

This keynote, and conference, is ideal for non-specialist investors wanting to dip their toes into biotech investing, as well as those more experienced and looking to inform their next investment.

With diverse experience in both public and private investments, Kanishka currently heads the public market efforts for Nextech Ventures, a cancer therapeutics-focused venture capital (VC) firm investing in drug discovery-stage companies with investments spanning company inceptions to crossover rounds.

Prior to this, Kanishka spent over a decade with BVF Partners, a premier biotechnology-focused hedge fund where he helped manage the growth of the fund from several hundred million to several billion under management, starting as an Analyst and being promoted to Managing Director.

Kanishka is the first keynote speaker announced for AusBioInvest 2023, a premier one-day event featuring keynote presentations and panel discussions from local and international life science investment specialists on topics including industry trends and market updates.

AusBioInvest 2023 directly connects the investment community with innovative companies, enabling Australian life science companies to present their business case in an eight-minute pitch to a room full of investors. Its business partnering system and on-site networking lounge offer additional networking opportunities for both investors and companies.

AusBiotech invites qualified investors, including venture capital firms, private equity investors, high-net-worth individuals, research analysts, brokers, family offices, to access their complimentary tickets to attend AusBioInvest 2023, providing them with a valuable opportunity to make meaningful connections with companies, hear the latest market updates, and explore potential investment prospects. Register your interest here.

Biotech companies are also being invited to register their interest to pitch at AusBioInvest 2023 to a global audience of investors, industry executives, and key stakeholders. Join the investee cohort alongside Arovella Therapeutics, Carina Biotech, Celosia Therapeutics, EncapSolutions, FivepHusion, Genofax, Immuron, InhaleRx, LBT Innovations, Microba, Noxopharm, Prescient Therapeutics, Snoretox Ltd, Tessara Therapeutics, and Vaxxas.

Delegates can also register now.

AusBioInvest 2023 is proudly supported by Host State Partner the Victoria State Government.